Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 7 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Antivirals Market to 2017 - Introduction | 11 | 1 |
| Introduction | 11 | 1 |
| GBI Research Report Guidance | 11 | 1 |
| Antivirals Market to 2017 - Market Overview | 12 | 8 |
| Market Forecasts | 12 | 1 |
| Revenue | 12 | 2 |
| Global Branded vs Generic Market Share | 14 | 1 |
| Annual Cost of Therapy | 15 | 1 |
| Treatment Usage Patterns | 16 | 1 |
| Diseased Population | 17 | 1 |
| Treatment Seeking Population | 17 | 1 |
| Diagnosed Population | 17 | 1 |
| Prescription Population | 17 | 1 |
| Drivers and Restraints for the Global Antivirals Therapeutics Market | 18 | 1 |
| Market Drivers | 18 | 1 |
| Increase in the Diseased Populations and Awareness Levels | 18 | 1 |
| Launch of New Drugs with Better Efficacy | 18 | 1 |
| Market Restraints | 19 | 1 |
| Patent Expiries and the Subsequent Entry of Generics | 19 | 1 |
| Social Stigma Associated with Treatment of HIV/AIDS and Herpes | 19 | 1 |
| Antivirals Market to 2017 - Geographical Landscape | 20 | 14 |
| Revenue Analysis by Geography | 20 | 2 |
| The US | 22 | 1 |
| Revenue | 22 | 1 |
| Annual Cost of Therapy | 23 | 1 |
| Treatment Usage Patterns | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Top Five Countries of Europe | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Therapy | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Diseased Population | 29 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 29 | 1 |
| Japan | 30 | 1 |
| Revenue | 30 | 1 |
| Annual Cost of Therapy | 31 | 1 |
| Treatment Usage Patterns | 32 | 1 |
| Diseased Population | 33 | 1 |
| Treatment Seeking Population | 33 | 1 |
| Diagnosed Population | 33 | 1 |
| Prescription Population | 33 | 1 |
| Antivirals Market to 2017 - Therapeutic Landscape | 34 | 50 |
| HIV/AIDS Therapeutics Market Forecasts | 34 | 1 |
| Introduction | 34 | 2 |
| Revenue | 36 | 2 |
| Branded vs Generic Market Share | 38 | 1 |
| Revenue Analysis by Country | 39 | 2 |
| Annual Cost of Therapy | 41 | 1 |
| Treatment Usage Patterns | 42 | 2 |
| Diseased Population | 44 | 1 |
| Treatment Seeking Population | 45 | 1 |
| Diagnosis Population | 46 | 1 |
| Prescription Population | 47 | 1 |
| Drivers and Restraints for the Global HIV/AIDS Therapeutics Market | 48 | 1 |
| Market Drivers | 48 | 1 |
| Increase in Awareness Levels of Disease Progression will Lead to an Increase in Treatment Seeking and Diagnosed Populations | 48 | 1 |
| New Product Launches will Increase Uptake and Drive the Market | 49 | 1 |
| Increase in Drug Prices will Drive Growth and Reduce the Impact of Generics | 50 | 1 |
| Market Restraints | 50 | 1 |
| Patent Expiries and the Subsequent Entry of Generics will Negatively Impact the Market | 50 | 1 |
| Social Stigma Associated with HIV/AIDS Leads to Low Treatment Seeking Rate | 51 | 1 |
| Rigorous and Complex Treatment Regimes Result in Poor Patient Compliance Leading to a Reduction in Drug Volumes | 51 | 1 |
| Hepatitis Therapeutics Market Forecasts | 52 | 1 |
| Introduction | 52 | 1 |
| Hepatitis A | 52 | 1 |
| Hepatitis B | 52 | 1 |
| Hepatitis C | 53 | 2 |
| Revenue | 55 | 2 |
| Branded vs Generic Market Share | 57 | 1 |
| Revenue Analysis by Country | 58 | 2 |
| Annual Cost of Therapy | 60 | 1 |
| Treatment Usage Patterns | 61 | 1 |
| Diseased Population | 62 | 1 |
| Treatment Seeking Population | 62 | 1 |
| Diagnosed Population | 62 | 1 |
| Prescription Population | 62 | 1 |
| Drivers and Restraints for the Global Hepatitis Therapeutics Market | 63 | 1 |
| Market Drivers | 63 | 1 |
| Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline | 63 | 1 |
| Promising Developments in Hepatitis C Pipeline | 63 | 1 |
| Steady Increase in Prescription Population | 63 | 1 |
| Market Restraints | 64 | 1 |
| Hepatitis is Rarely Recognized During the Early Stages of the Disease Due to Lack of Symptoms during Acute Phase | 64 | 1 |
| Low Treatment Seeking Population | 64 | 1 |
| Loss of Exclusivity Protection in Hepatitis B Market | 64 | 1 |
| Herpes Therapeutics Market Forecasts | 64 | 1 |
| Introduction | 64 | 1 |
| Herpes Simplex Infection | 64 | 2 |
| Herpes Zoster Infection | 66 | 1 |
| Revenue | 67 | 1 |
| Branded vs Generic Market Share | 68 | 1 |
| Revenue Analysis by Country | 69 | 2 |
| Annual Cost of Therapy | 71 | 1 |
| Treatment Usage Pattern | 72 | 1 |
| Diseased Population | 73 | 1 |
| Treatment Seeking Population | 73 | 1 |
| Diagnosed Population | 73 | 1 |
| Prescription Population | 73 | 1 |
| Drivers and Restraints for the Global Herpes Therapeutics Market | 73 | 1 |
| Market Drivers | 73 | 1 |
| Increase in the Diseased Population | 73 | 1 |
| Increase in Elderly and Immunosuppressed Population | 73 | 1 |
| Market Restraints | 74 | 1 |
| Low Diagnosis Rate and Lack of Awareness | 74 | 1 |
| Social Stigma Associated with Treatment of Herpes Simplex Infections | 74 | 1 |
| Influenza Therapeutics Market Forecasts | 75 | 1 |
| Introduction | 75 | 2 |
| Revenue | 77 | 1 |
| Branded vs Generic Market Share | 78 | 1 |
| Revenue Analysis by Country | 79 | 1 |
| Annual Cost of Therapy | 80 | 1 |
| Treatment Usage Patterns | 81 | 1 |
| Diseased Population | 82 | 1 |
| Treatment Seeking Population | 82 | 1 |
| Diagnosed Population | 82 | 1 |
| Prescription Population | 82 | 1 |
| Drivers and Restraints for the Global Influenza Therapeutics Market | 83 | 1 |
| Market Drivers | 83 | 1 |
| Launch of New Drugs with Better Efficacy | 83 | 1 |
| Threat of Pandemic Influenza | 83 | 1 |
| Market Restraints | 83 | 1 |
| Increase in Vaccine Coverage Resulting in Decrease in Therapeutics Market | 83 | 1 |
| Expected Patent Expiry of Tamiflu in 2016 and Relenza in 2014 | 83 | 1 |
| Antivirals Market to 2017 - Pipeline Analysis | 84 | 38 |
| R&D Pipeline by Phase | 84 | 1 |
| R&D Pipeline by Indication | 85 | 1 |
| R&D Pipeline - HIV/AIDS | 86 | 1 |
| Overview | 86 | 1 |
| Pipeline by Clinical Phase of Development | 87 | 1 |
| Discovery | 87 | 1 |
| Preclinical | 88 | 1 |
| Phase I | 89 | 1 |
| Phase II | 90 | 1 |
| Phase III | 91 | 1 |
| Promising Molecules under Development - HIV/AIDS | 92 | 1 |
| Quad | 92 | 1 |
| Overview | 92 | 1 |
| Efficacy | 92 | 1 |
| Safety | 92 | 1 |
| Clinical Trial Details | 92 | 1 |
| Elvitegravir | 92 | 1 |
| Overview | 92 | 1 |
| Efficacy | 92 | 1 |
| Safety | 92 | 1 |
| Clinical Trial Details | 92 | 1 |
| GSK1349572 | 93 | 1 |
| Overview | 93 | 1 |
| Efficacy | 93 | 1 |
| Safety | 93 | 1 |
| Clinical Trial Details | 93 | 1 |
| R&D Pipeline - Hepatitis | 94 | 1 |
| Overview | 94 | 1 |
| R&D Pipeline by Indications | 95 | 1 |
| Hepatitis B Therapeutics Pipeline | 96 | 1 |
| Hepatitis B Vaccines Pipeline | 97 | 1 |
| Hepatitis C Therapeutics Pipeline | 98 | 6 |
| Promising Molecules under Development - Vaccines for Hepatitis B | 104 | 1 |
| Heplisav | 104 | 1 |
| Overview | 104 | 1 |
| Efficacy | 104 | 1 |
| Safety | 104 | 1 |
| Clinical Study Details | 104 | 1 |
| Spi-VEC | 105 | 1 |
| Overview | 105 | 1 |
| Efficacy | 105 | 1 |
| Safety | 105 | 1 |
| Clinical Study Details | 105 | 1 |
| Promising Molecules under Development - Therapeutics for Hepatitis B | 105 | 1 |
| Entecavir plus Adefovir Combination Therapy | 105 | 1 |
| Overview | 105 | 1 |
| Efficacy | 105 | 1 |
| Safety | 105 | 1 |
| Clinical Study Details | 105 | 1 |
| Tenofovir plus Emtricitabine Combination Therapy | 106 | 1 |
| Overview | 106 | 1 |
| Efficacy | 106 | 1 |
| Safety | 106 | 1 |
| Clinical Study Details | 106 | 1 |
| Pegylated Interferon Alfa-2a + Adefovir | 106 | 1 |
| Overview | 106 | 1 |
| Efficacy | 106 | 1 |
| Safety | 106 | 1 |
| Clinical Study Details | 106 | 1 |
| Promising Molecules under Development - Therapeutics for Hepatitis C | 107 | 1 |
| Zalbin (albinterferon alfa-2b, Joulferon) | 107 | 1 |
| Introduction | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| Clinical Trial Management | 107 | 1 |
| RG 7128 | 108 | 1 |
| Introduction | 108 | 1 |
| Mechanism of Action | 108 | 1 |
| Clinical Trial Management | 108 | 1 |
| R&D Pipeline - Herpes | 109 | 1 |
| Overview | 109 | 1 |
| R&D Pipeline by Indication | 110 | 1 |
| Herpes Simplex - Pipeline by Clinical Phase of Development | 110 | 1 |
| Discovery and IND Filed | 110 | 1 |
| Preclinical | 111 | 1 |
| Phase I | 111 | 1 |
| Phase II | 111 | 1 |
| Phase III and NDA Filed | 112 | 1 |
| Herpes Zoster - Pipeline by Clinical Phase of Development | 112 | 1 |
| Pre-Clinical and Phase II | 112 | 1 |
| Phase III | 112 | 1 |
| Promising Molecules under Development - Herpes | 113 | 1 |
| BA-021 | 113 | 1 |
| Introduction | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| Clinical Development | 113 | 1 |
| NB-001 | 113 | 1 |
| Introduction | 113 | 1 |
| Mechanism of Action | 113 | 1 |
| Clinical Development | 114 | 1 |
| ARYS-01 | 114 | 1 |
| Introduction | 114 | 1 |
| Mechanism of Action | 114 | 1 |
| Clinical Development | 114 | 1 |
| GSK 1437173A | 115 | 1 |
| Introduction | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| Clinical Development | 115 | 1 |
| V212 | 115 | 1 |
| Introduction | 115 | 1 |
| Mechanism of Action | 115 | 1 |
| Clinical Development | 115 | 1 |
| R&D Pipeline - Influenza | 116 | 1 |
| Overview | 116 | 1 |
| Pipeline by Clinical Phase of Development | 117 | 1 |
| Discovery | 117 | 1 |
| Preclinical | 118 | 1 |
| Phase I | 119 | 1 |
| Phase II | 119 | 1 |
| Phase III/NDA Filed | 120 | 1 |
| Promising Molecules under Development - Influenza | 120 | 1 |
| S-021812 | 120 | 1 |
| Overview | 120 | 1 |
| Clinical Trial Details | 120 | 1 |
| CS-8958 | 121 | 1 |
| Overview | 121 | 1 |
| Clinical Trial Details | 121 | 1 |
| T-705 | 121 | 1 |
| Overview | 121 | 1 |